地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18327026838
传真:13212737804
邮箱:sales@amyjet.com

艾美捷科技代理ChemGenes品牌。
ChemGenes在核苷和核苷酸化学方面拥有超过40年的经验。ChemGenes提供高质量、高度修饰的寡核苷酸,包括任何类型的RNA/DNA嵌合体和荧光标记探针。ChemGenes成立于1981年,是世界上经验最丰富的DNA和RNA制造公司之一。作为近半个世纪以来核酸研究和合成的开拓者,ChemGenes在核酸化学领域赢得了市场领导者的地位。ChemGenes帮助推出了至关重要的新药,并制造了用于拯救生命的新冠肺炎疫苗和诊断的关键材料,这一成就具有真正的全球影响。产品包括:
(1)寡核苷酸合成试剂(Oligonucleotide Synthesis Reagents)
Natural DNA
Modified DNA
Natural RNA
Modified RNA
2' & 3' -O-Methyl RNA
CombiClick, Combinatorial Click Chemistry
Chromophores & Ligands
Ancillary Reagents
Post Synthesis, Purification, and Accessories
Morpholinos
(2)寡核苷酸(Oligonucleotides)
(3)单核苷酸和核苷(Mononucleotides & Nucleosides)
Standard Nucleosides, unprotected
Modified Nucleosides, unprotected
Partially Protected Nucleosides
DMT Protected deoxy Nucleosides
DMT Protected ribo Nucleosides
DMT Protected 2'-O-Protected Nucleosides
Triphosphates
(4)其他试剂
NHS Esters
Nitrogenous base
Phosphoramidite Chemistry Reagents
Sugars & Purines
< " data-original="http://biogradetech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理ChemGenes品牌"> 艾美捷科技代理ChemGenes品牌
日本和光纯药工业株式会社“Wako”系列试剂涵盖了全面的生物化学、分析化学、有机化学、环境分析、食品·医药品分析、高纯度及认证标准品等多类,约50万种试剂。Wako尤以致力于某些当前特殊的高端领域,如:癌症病的研究及有效防治、农兽药残留物分析、中药研究、食品科学和水质分析等关乎人类健康的生命科学研究,并且独树一帜,经历大量成功实验应用案例从而奠定了其在试剂领域中强而有力的地位。
Wako的主要产品包括:
生物化学类
分析化学类
环境分析用试剂
合成用试剂
素材研究用试剂
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://biogradetech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Wako"> Wako
艾美捷科技代理Eagle Biosciences公司产品。
Eagle Biosciences公司是多种ELISA试剂盒的领先供应商,产品包括:高效液相色谱法测定试剂盒、ELISA检测试剂盒,抗体和蛋白质。
Eagle Biosciences has quickly become a leading provider of immunoassays, antibodies, and proteins to the worldwide research and clinical communities. Our staff has over 25 years in both the research and diagnostics industries with over 10 years in commercialization and distribution. We offer EagleBio developed products in addition to distributing products from over twenty European organizations. With all of these offerings, we keep our primary focus on providing esoteric and innovative products that aid medical research and clinical laboratories.
Eagle Biosciences公司的主要产品包括:
Bone Metabolism Kits
Cancer Biomarker Kits
Cardiovascular Assay Kits
Drug Monitoring Assay Kits
Endocrine Assay Kits
GastroIntestinal Assays
Immunology Assay Kits
Neurobiology Assay Kits
Antibodies
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://biogradetech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

艾美捷科技代理Sorachim品牌。
Sorachim公司提供诊断试剂专用酶:脂肪酶、过氧化物酶、尿酸酶,辅酶:NADH、NADPH、NADP;底物:TMB、双甘氨肽等 IVD 行业专用试剂。Sorachim 是一家专注于为制药、生物技术、化妆品和食品行业提供高质量化学原料和定制化解决方案的公司。公司成立于 1986 年,总部位于法国,凭借其广泛的产品组合、严格的质量控制和卓越的客户服务,已成为欧洲化学原料领域的重要供应商之一。Sorachim 的产品广泛应用于药物开发、化妆品配方、食品添加剂和工业应用等领域,包括:
制药原料:Sorachim 提供用于药物开发的化学原料,包括活性药物成分(API)、中间体、辅料和溶剂。
化妆品原料:提供用于化妆品配方的化学原料,如乳化剂、增稠剂、防腐剂和功能性添加剂。
食品添加剂:提供用于食品工业的化学原料,如乳化剂、稳定剂、防腐剂和香料。
工业化学品:公司为工业应用提供特种化学品,如表面活性剂、溶剂、涂料和油墨添加剂。
<< " data-original="http://biogradetech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Sorachim品牌"> 艾美捷科技代理Sorachim品牌

艾美捷科技有限公司代理Mimotopes公司多肽及多肽合成相关产品。Mimotopes公司位于澳大利亚,可以提供2000余种多肽,100余种药物及化妆品肽,1000余种各类氨基酸及多肽合成用试剂。
Mimotopes公司的主要产品类别:
(1)多肽(Peptides)
库存普通多肽(Catalogue Peptides)
化妆品肽(Cosmetic Peptides)
药物肽(Pharmaceutical Peptides)
肽库(Off-the-Shelf Library)
(2)氨基酸(Amino Acids)
Z Amino Acids
Unusual Amino Acids
N methyl Amino Acids
Fmoc Amino Acids
Common Amino Acids
Boc amino acids
AA attached_to_2-Chlorotrityl_Resin
AA attached_to_Wang_Resin
(3)多肽合成试剂(Peptides Synthesis Reagents)
Coupling Reagents
Amino Alcohols
General Reagents
Linkers
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

Calbiotech是为世界各地的大学和研究中心定制开发和制造免疫产品的主要参考实验室,产品包括ELISA、超灵敏的化学发光试剂,IVD RIA和PCR试剂盒。
Calbiotech specializes in immunoassay development and manufacturing, with a comprehensive range of ELISA and CLIA assays for human and animal research, including specific assays for hormone, autoimmune disorders, cancer, infectious diseases and much more. The company has over 200 products which are distributed to over 80 countries globally.
Calbiotech is a key partner for biotech, pharma and CROs, providing contract manufacturing and assay development services, including custom coated microplates, reagents, buffers and other assay components.
Calbiotech的主要产品包括:
(1)ELISA KITS
Products For Research
Products For Export
(2)DEVELOPMENT REAGENTS
Coated Plates
Coating & Blocking Buffers
Stabilizers & Substrates
Sample Prep & Assay Optimization
Commons: Wash, Stop, TMB, PBS
(3)CHEMILUMINESCENT
SAV Coated Magnetic Beads
Chemiluminescent Immunoassays
" data-original="http://biogradetech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Calbiotech"> Calbiotech
PhytoTechnology(简称PhytoTech)公司是一家专门从事于研发和生产植物组织培养基,植物学技术相关产品的一家科研生产性企业。由Dr. Kenneth C. Torres博士和他的妻子Janet 于1997年在美国Lenexa, Kansas州创立,随着公司产品的不断改进和更新,目前PhytoTech公司已经成为了世界上著名的植物生物学类产品的生厂商和原料供应商,其公司产品以稳定的质量和优质的价格已赢得了世界范围内众多客户的认可,并在植物学的各个领域内广泛使用。
PhytoTechnology Laboratories manufactures and distributes products to the plant tissue culture, plant biotechnology, and plant science markets. Our products are used to mass propagate plants on sterile culture media in laboratory settings. We also supply products for the genetic improvement of plants through gene transformation research. Manufacturing, product development, administration and distribution of products are all performed at the PhytoTechnology Laboratories campus (20,000 square feet of production and research and development space) in Overland Park, a suburb of the Kansas City metro area in Kansas. This central US location provides direct access to most major markets around the world.
PhytoTechnology公司主要产品包括:
Plant Media
Biochemicals
Molecular Biology
Microbiology
Phytopathology
Phycology
Seed Testing
Kits Equipment
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

艾美捷科技代理BBI Solutions品牌诊断原料。
BBI Solutions的产品范围广泛,包括人的抗原、抗体、血清、血浆和临床化学酶等优质原料,还生产世界知名的ELISA试剂盒、生物传感器的标签、黄金纳米粒子和葡萄糖氧化酶等。BBI Solutions提供一系列专业的服务,包括抗体开发、抗体制造、抗原定制、金共轭化等。其独特的抗体开发、侧向流动试验开发和制造服务组合,能够支持客户从概念到商业化的全过程。BBI Solutions拥有专业的研究团队和完善的生产和质控流程,确保了公司产品的高品质。其提供的技术支持涵盖了产品的应用验证、配对使用抗体的推荐等方面,为客户提供了全方位的技术保障。BBI Solutions公司提供试剂专用酶:辣根过氧化物酶、谷氨酸脱氢酶、碱性磷酸酶、尿素酶、胆固醇酯酶,聚链霉亲和素,人源蛋白,单克隆抗体,金纳米颗粒等。
<<< " data-original="http://biogradetech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理BBI Solutions品牌诊断原料"> 艾美捷科技代理BBI Solutions品牌诊断原料

Zedira是一家临床阶段的生物技术公司,专门从事转谷氨酰胺酶的研究,开发一系列小分子药物候选物。Zedira公司正致力于药物发现的前沿领域,该领域涉及阻止调节失调的转谷氨酰胺酶的小分子。此外,Zedira是一个全球品牌,专门用于转谷氨酰胺酶领域的研发和诊断试剂,其独特和高质量的产品有助于推动转谷氨酰胺酶的研究和应用。
Zedira is a clinical stage biotech company specialised in transglutaminase. Zedira conducts its own development of small molecular drug candidates. In doing so, the company is working at the cutting edge of drug discovery involving small molecules that block dysregulated transglutaminases. In addition, Zedira is a global brand for specialty reagents for research & development as well as diagnostics in the transglutaminase field. Numerous unique and high quality products help pushing forward transglutaminase-related science – both in academia and industry.
Zedira公司主要产品:
Transglutaminases
Microbial Transglutaminase
Assays and Substrates
Inhibitors
Antibodies and Microarrays
Proteases
Protein Labeling
Blood Coagulation
Cereal Proteins
Celiac Disease Products
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
Zedira产品详情请咨询我司客服人员:
| 产品编号 | 产品名称 | 产品规格 |
| A003 | Polyclonal antibody to human tissue transglutaminase (TG2) | 100 ug |
| A004 | Monoclonal antibody to tissue transglutaminase (TG2) | 100 ug |
| A008 | Polyclonal antibody to human transglutaminase 5 (TG5) | 500 ug |
| A011 | Monoclonal antibody to gliadin (clone XGY1) | 1 mg |
| A013 | Monoclonal antibody to gliadin (clone XGY7) | 1 mg |
| A014 | Polyclonal antibody to human tissue transglutaminase (TG2) | 500 ug |
| A015 | Polyclonal antibody to human epidermal transglutaminase (TG3) | 500 ug |
| A016 | Polyclonal antibody to human blood coagulation factor XIII (A-subunit) | 500 ug |
| A017 | Polyclonal antibody to human neuronal transglutaminase (TG6) | 500 ug |
| A018 | Polyclonal antibody to human keratinocyte transglutaminase (TGI) | 500 ug |
| A020 | Polyclonal antibody to microbial protransglutaminase (pro-MTG, pro-BTG) | 500 ug |
| A021 | Polyclonal antibody to human plasminogen (rhPLG) | 500 ug |
| A022 | Polyclonal antibody to human prostate transglutaminase (TG4) | 500 ug |
| A023 | Monoclonal antibody to N'-ly-L-glutamylpL-lysine-isopeptide bond | 100 ug |
| A024 | Monoclonal Antibody to microbial (bacterial) Transglutaminase | 100 ug |
| A028 | FITC-labeled polyclonal antibody to human TG2 | 200 ug |
| A029 | FITC-labeled polyclonal antibody to human TGI | 200 ug |
| A030 | FITC-labeled polyclonal antibody to human TG3 | 200 ug |
| A031 | FITC-labeled polyclonal antibody to human TG6 | 200 ug |
| A032 | FITC-labeled polyclonal antibody to human factor XIII (A-subunit) | 200 ug |
| A033 | Monoclonal antibody to human TG2 (Catalytic Domain, clone XTG17) | 200 ug |
| A034 | Monoclonal antibody to human TG2 (Beta Sheet Domain, clone XTG 1 1) | 200 ug |
| A035 | Monoclonal antibodies to gliadin (Set No 1) | 1 Set |
| A036 | Monoclonal antibody to human TG2 (Beta Barrel 1 Domain, clone XTG21) | 200 ug |
| A037 | Monoclonal antibody to human TG2 (Beta Barrel 2 Domain, clone XTG1 8) | 200 ug |
| A040 | Polyclonal antibody to human transglutaminase 7 (TG7) | 200 ug |
| A042 | Monoclonal antibody to human TGI (clone XTG3 1) | 200 ug |
| A044 | FITC-labeled polyclonal antibody to human TG5 | 200 ug |
| A046 | D-Dimer monoclonal mouse antibody, clone 3B6 | 100 ug |
| A047 | D-Dimer monoclonal mouse antibody, clone 1 D2 | 100 ug |
| A051 | Biotinylated polyclonal antibody to microbial transglutaminase (MTG) | 50 ug |
| A052 | Biotinylated polyclonal antibody to human factor XIII (A-subunit) | 50 ug |
| A053 | Biotinylated polyclonal antibody to human TG2 | 50 ug |
| A054 | Monoclonal antibody to gliadin (clone XGY6) | 1 mg |
| A057 | Monoclonal antibody to deamidated gliadin | 100 ug |
| A058 | Monoclonal antibody to gliadin (clone XGY5) | 1 mg |
| A059 | Monoclonal antibody to gliadin (clone XGY9) | 1 mg |
| A060 | Monoclonal antibody to gliadin (clone XGY10) | 1 mg |
| A061 | Monoclonal antibody to gliadin (clone XGY 1 6) | 1 mg |
| A062 | Monoclonal antibody to deamidated and non-deamidated gliadin | 100 ug |
| A063 | Monoclonal antibody to gliadin (clone XGY2) | 1 mg |
| A064 | Monoclonal antibody to gliadin (clone XGY4) | 1 mg |
| A065 | Monoclonal antibody to gliadin (clone XGY8) | 1 mg |
| A066 | Monoclonal antibody to gliadin (clone XGY 1 2) | 1 mg |
| A067 | Monoclonal antibody to gliadin (clone XGY 1 5) | 1 mg |
| A068 | Monoclonal antibody to gliadin (clone XGY 1 7) | 1 mg |
| A069 | Monoclonal antibody to gliadin (clone XGY23) | 1 mg |
| A070 | Monoclonal antibody to gliadin (clone XGY24) | 1 mg |
| A071 | Monoclonal antibody to hordein (clone XH4) | 1 mg |
| A072 | polyclonal antibody to mouse tissue Transglutaminse | 200 ug |
| A074 | Polyclonal antibody to human blood coagulation factor XIII (B-subunit) | 200 ug |
| A075 | FITC-labeled polyclonal antibody to mouse TG2 | 200 ug |
| A076 | DD-XLink-mab | 100 ug |
| A077 | FITC-labeled polyclonal antibody to human factor XIII (B-subunit) | 200 ug |
| A078 | Polyclonal antibody to human epidermal transglutaminase (TG3) Protein A | 250 ug |
| A079 | Biotin-DD-XLink-mab | 50 ug |
| A082 | Monoclonal antibody to human TG3 (clone XTG45) | 200 ug |
| A101 | FXIII-Assay Substance, Abz-NE(CAD-DNP)EQVSPLTLLK-OH | 10 mg |
| A102 | TG2-Assay Substance. Abz-APE(CAD-DNP)QEA-OH | 10 mg |
| A105 | NQEQVSPLTLLK, alpha2-Antiplasmin peptide (1-12) | 25 mg |
| A106 | (ATTO-48 8TM)cadaveri ne | 1 mg |
| A108 | Ac-(D)-Asp-MA-N le-Nle-Leu-Pro-Trp-Pro-OH | 5 mg |
| A109 | β-Amyloid peptide 1-42 (Aβ 1-42) | 1 mg |
| A112 | (ATTO-532)cadaverine | 1 mg |
| A113 | (ATTO-550)cadaverine | 1 mg |
| A114 | (AnO-647N)cadaverine | 1 mg |
| A115 | (ATTO-700)cadaverme | 1 mg |
| A125 | Factor XIII activation peptide | 10 mg |
| A132 | Ac-WALQRPHYSYPD | 10 mg |
| A139 | Monoclonal antibody to human TG6 (Catalytic Domain, clone XTG52) | 200 ug |
| A140 | Monoclonal antibody to human TG6 (Beta Barrel 1 Domain, clone XTG39) | 200 ug |
| A141 | Monoclonal antibody to human TG6 (Beta Barrel 1 Domain, clone XTG68) | 200 ug |
| A142 | Monoclonal antibody to human TG6 (Beta Barrel 2 Domain, clone XTG57) | 200 ug |
| A143 | Monoclonal antibody to microbial Transglutaminase (clone XM67) | 200 ug |
| A144 | Monoclonal antibody to microbial Transglutaminase (clone XM68) | 200 ug |
| A145 | Polyclonal Antibody to microbial Transglutaminase | 200 ug |
| A152 | 3-Azido-l -propanamine | 100 mg |
| A153 | 4-Azidobutan-l-amine | 100 mg |
| A154 | Monoclonal antibody to human factor XIII (Activation Peptide, clone XTG09) | 200 ug |
| A155 | Monoclonal antibody to human factor XIII (Catalytic Domain, clone XTG02) | 200 ug |
| B001 | Biotinyl-Thr-Val-GIn-GIn-Glu-Leu-OH | 5 mg 25 mg |
| B002 | N-(Biotinyl)cadaverine | 25 mg 100 mg |
| B003 | Boc-DON-Gln-lle-Val-OMez "Boc-DON” | 10 mg |
| B006 | Thr-Val-Gln-Gln-Glu-Leu-OH | 25 mg |
| B007 | Keratinocyte transglutaminase (TGI )-substrate-peptide K5 | 10 mg |
| B008 | Tissue transglutaminase (TG2)-substrate-peptide T26 | 10 mg |
| B009 | Epidermal transglutaminase (TG3)-substrate-peptide E51 | 10 mg |
| B010 | Blood coagulation FXIII-substrate-peptide Fl 1 KA | 10 mg |
| B013 | Neuronal transglutaminase (TG6)-substrate peptide Y25 | 10 mg |
| B014 | Transglutaminase 7 (TG7)-substrate peptide Z3S | 10 mg |
| B015 | Biotin-Ahx-MA-QPL-OMe | 10 mg |
| B017 | Microbial Transglutaminase (MTG)-substrate peptide M48 | 10 mg |
| B019 | Biotin-Ahx-QVPL-OMe | 10 mg |
| C001 | Z-GIn-Gly-OH | 1g |
| C002 | Z-GIn-Gly-CAD-DNS | 25 mg 100 mg |
| C074 | Z-Gln-Gly-CAD-(AnO-488) | 1 mg |
| C075 | Z-Gln-Gly-CAD-(ATTO-532) | 1 mg |
| C076 | Z-Gln-Gly-CAD-(AnO-550) | 1 mg |
| C077 | Z-Gln-Gly-CAD-(ATTO-647N) | 1 mg |
| C078 | Z-Gln-Gly-CAD-(AnO-700) | 1 mg |
| C079 | Z-GIn-Gly-PEG(3)-N3 | 25 mg |
| C080 | Z-Gln-Gly-PEG(11)-N3 | 25 mg |
| C090 | Z-GIn-Gly-CAD-TAMRA | 25 mg |
| C091 | Z-GIn-Gly-CAD-Biotin | 25 mg |
| C092 | Z-Gln-Gly-(PEG1,088), monodisperse | 25 mg |
| C093 | Z-Gln-Gly-(PEG5,000), polydisperse | 25 mg |
| C094 | Tosyl-ε-aminopentyl-CMK | 1 mg |
| C095 | Dansyl-ε-aminopentyl-CMK | 1 mg |
| C102 | MTG Blocker | 10 mg 25 mg |
| D001 | Dansyl-ε-aminohexanoyl-GIn-GIn-lle-Val-OH | 25 mg 100 mg |
| D002 | N-(2,4-Dinitrophenyl)cadaverine | 100 mg |
| D003 | 1,3-Dimethyl-2[(2-oxo-propyl)thio]imidazolium chloride | 100 mg |
| D004 | 1,3-Dimelhyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium | 10 mg |
| D005 | Metalloprotease-Assay-Substance, DABCYL-Ser-Phe-EDANS | 2 mg |
| D006 | N-(Dansyl)cadaverine | 100 mg |
| D007 | Cadaverine | 100 mg |
| D008 | "DALP", DNP-aminohexanoic acid-Lys-aminopropanol | 5 mg |
| D009 | DALP-methyl carbamate | 5 mg |
| D0I 6 | LDN 27219 | 10 mg |
| E018 | ZediXclusive Tissue Transglutaminase EIA | 1 Kit |
| E021 | ZediXclusive Microbial Transglutaminase (MTG) ELISA | 1 Kit |
| E103 | ZediXclusive TG6-ab ELISA (IgA) | 1 Kit (96 wells) |
| E104 | ZediXclusive TG6-ab ELISA (IgG) | 1 Kit (96 wells) |
| F001 | FXIII-Assay Kit | 1 Kit |
| F002 | Tissue Transglutaminase Assay Kit | 1 Kit |
| F004 | Fibrinogen, purified from human plasma | 50 mg |
| F006 | FITC-labeled Fibrinogen | 5 mg |
| F007 | Fibrin Glue (porcine) | 1 Kit |
| F008 | Fibrin Glue (bovine) | 1 Kit |
| F011 | Cross-linked fibrin degradation products, xFDPs | 200 ug |
| F012 | Fibrin degradation products, FDPs | 200 ug |
| G001 | Alpha2-gliadin, 33mer (aa56-88), biotinylated | 5 mg |
| G002 | Deamidated alpha2-gliadin, 33mer (aa56-88), biotinylated | 5 mg |
| G003 | Ac-PLQPEQPFPK(ε-Biotin), Deamidated gliodin peptide | 10 mg |
| G004 | Ac-PEQLPQFEEK(ε-Biotin), Deamidated gliadin peptide | 10 mg |
| G005 | DGPx4 (Fusion protein of 4 deamidated gliadin peptides) | 500 ug |
| G006 | DGPx2 (Fusion protein of 2 deamidated gliadin peptides) | 500 ug |
| G007 | DGPxl (deamidated gliadin peptide) | 500 ug |
| G008 | Omega-5 gliadin | 500 ug |
| G009 | Alpha2-gliadin, 33mer (aa 56-88) | 5 mg |
| G011 | Deamidated alpha2-gliadin, 33mer, (Acetyl-aa56-88-amide, Q65E) | 5 mg |
| G013 | QPFPQPQLPYPQPQ-amide | 10 mg |
| G014 | QPFPQPELPYPQPQ-amide | 10 mg |
| G017 | Biotinylated DGPx1 | 100 ug |
| G018 | Barley albumin and globulin | 5 mg |
| G019 | Barley prolamin (Hordein) | 5 mg |
| G020 | Barley glutelin (Hordenin) | 5 mg |
| G021 | Rye albumin and globulin | 5 mg |
| G022 | Rye prolamin (Secalin) | 5 mg |
| G023 | Rye glutelin (Secalinin) | 5 mg |
| G024 | Corn albumin and globulin | 5 mg |
| G025 | Corn prolamin (Zein) | 5 mg |
| G026 | Corn glutelin (Zeanin) | 5 mg |
| G027 | Rice albumin and globulin | 5 mg |
| G028 | Rice prolamin (Oryzin) | 5 mg |
| G029 | Rice glutelin (Oryzenin) | 5 mg |
| G030 | Spell albumin and globulin | 5 mg |
| G031 | Spelt prolamin | 5 mg |
| G032 | Spelt glutelin | 5 mg |
| G033 | Oat albumin and globulin | 5 mg |
| G034 | Oat prolamin (Avenin) | 5 mg |
| G035 | Oat glutelin (Avenalin) | 5 mg |
| G036 | Wheat albumin and globulin (Leukosin and Edestin) | 5 mg |
| G037 | Wheat prolamin (Gliadin) | 5 mg |
| G038 | Wheat glutelin (Glutenin) | 5 mg |
| G039 | Durum wheat albumin and globulin | 5 mg |
| G040 | Durum wheat prolamin | 5 mg |
| G041 | Durum wheat glutelin | 5 mg |
| G042 | Soy protein, saline soluble fraction | 5 mg |
| G043 | Soy protein, ethanol soluble fraction | 5 mg |
| G044 | Soy protein, propanol/urea/DTE soluble fraction | 5 mg |
| G045 | Millet (Sorghum) albumin and globulin | 5 mg |
| G046 | Millet (Sorghum) prolamin (Kafirin) | 5 mg |
| G047 | Millet (Sorghum) glutelin | 5 mg |
| G048 | L-Glutamic acid γ-monohydroxamate | 100 mg |
| G051 | 26mer gliadin peptide | 250 ug |
| G052 | 33mer gliadin peptide | 250 ug |
| G054 | 33mer DGP | 250 ug |
| G055 | Carrier protein control | 250 ug |
| G056 | DGP and Gliadin peptides (Set No 1) | 1 Set |
| G057 | Alpha2-gliadin, 33mer (aa56-88), TAMRA labeled | 5 mg |
| G058 | Alpha2-gliadin, 33mer (aa56-88), TAMRA and Biotin labeled | 5 mg |
| G101 | Gly-Pro-Arg-Pro-amide | 25 mg |
| I001 | Involucrme, recombinant human | 500 ug |
| K004 | "KxD", Boc-Lys-en-DNS | 10 mg |
| L001 | Substrate Finder Kit | 1 Kit |
| L101 | Biotin TGase Protein Q-Labeling Kit | 1 Kit |
| L102 | PEG1,088 TGase Protein Q-Labeling Kit | 1 Kit |
| L103 | PEG5,000 TGase Protein Q-Labeling Kit | 1 kit |
| L104 | ATTO-488™ TGase Protein Q-Labeling Kit | 1 Kit |
| L105 | ATTO-532™ TGase Protein Q-Labeling Kit | 1 Kit |
| L106 | ATTO-550™ TGase Protein Q-Labeling Kit | 1 Kit |
| L107 | ATTO-647N™ TGase Protein Q-Labeling Kit | 1 Kit |
| L108 | ATTO-700™ TGase Protein Q-Labeling Kit | 1 Kit |
| L201 | Biotin TGase Protein K-Labeling Kit | 1 Kit |
| L202 | PEG1,088 TGase Protein K-Labeling Kit | 1 Kit |
| L203 | PEG5,000 TGase Protein K-Labeling Kit | 1 Kit |
| L204 | ATTO-488™ TGase Protein K-Labeling Kit | 1 Kit |
| L205 | ATTO-532™ TGase Protein K-Labeling Kit | 1 Kit |
| L206 | ATTO-550™ TGase Protein K-Labeling Kit | 1 Kit |
| L207 | ATTO-647N™ TGase Protein K-Labeling Kit | 1 Kit |
| L208 | ATTO-700™ TGase Protein K-Labeling Kit | 1 Kit |
| M001 | MTG-ANiTA-Kit | 1 Kit |
| M003 | Tissue Transglutaminase Pico-Assay Kit | 1 Kit |
| P003 | Prolylendopeptidase from Myxococcus xanthus, recombinant | 150U |
| P004 | PT-Gluten | 1 mg 10 mg |
| P009 | human Pro-Glu-Plasminogen, recombinant | 100 ug |
| P010 | (PEG1,088)amine, monodisperse | 10 mg |
| P011 | (PEG5,000)amine, polydisperse | 10 mg |
| P012 | human Plasmin, recombinant | 100 ug |
| P0U | Urokinase | 1 mg |
| P015 | Streptokinase (bacterial plasminogen activator) | 1 mg |
| P016 | Tissue Plasminogen Activator | 100 ug |
| P111 | PEPperCHIP Pan-Transglutaminase Microarray | 1 Chip |
| P112 | PEPperCHIP Custom Transglutaminase Microarray | 1 Chip |
| P113 | PEPperCHIP Transglutaminase Microarray Service | 1 Sample |
| P114 | PepSlide Analyzer | 3-Month/1-Year/Perpetual License |
| P115 | PEPperCHIP Incubation Tray 3/1 | 1 Tray |
| P116 | PEPperCHIP Staining Kit | 1 Kit |
| P117 | PEPperCHIP Transglutaminase 2 Microarray | 1 Chip |
| P118 | PEPperCHIP Incubation Tray 3/5 | 1 Tray |
| R001 | N-(Tetrametylrhodaminyl)cadaverine | 10 mg |
| R002 | TAMRA-DON | 5 mg 10 mg |
| T001 | Microbial (bacterial) transglutaminase | 25 U; 1 x 250 U;10x 25 U; lx 500 U; 20x 25 U |
| T002 | Human tissue transglutaminase (TG2) | 250 ug 1mg |
| T004 | N-(p-Tosyl)-Gly-Pro-Lys-pNA | 25 mg |
| T006 | Guinea pig liver transglutaminase | 10U |
| T009 | Human keratinocyte transglutaminase (TG1) | 150 ug |
| T011 | Human transglutaminase 7 | 250 ug |
| T013 | Human epidermal transglutaminase, Dispose activated | 200 ug |
| T016 | Microbial (bacterial) Pro-transglutaminase | 250 ug |
| T018 | Inactive human tissue transglutaminase | 250 ug 1 mg |
| T021 | Human neuronal transglutaminase (TG6) | 250 ug |
| T022 | Human tissue transglutaminase (TG2) | 250 ug 1 mg |
| T024 | Human epidermal transglutaminase (TG3) | 200 ug |
| T027 | Human blood coagulation Factor Xlll-A z recombinant | 200 ug |
| T034 | Human tissue transglutaminase (TG2) | 100 ug |
| T035 | Human keratinocyte transglutaminase (TGI) | 150 ug |
| T036 | Transglutaminase Assay Kit, fluorescent, Casein, Dansylcadaverine | 1 Kit |
| T038 | Rat tissue transglutaminase | 250 ug 1 mg |
| T039 | Guinea pig liver transglutaminase, recombinant | 10U |
| T040 | Mouse tissue transglutaminase | 250 ug 1 mg |
| T042 | Human prostate Transglutaminase (TG4) | 100 ug |
| T050 | Human blood coagulation Factor XIII B subunit | 200 ug |
| T051 | Open tTG™ | 250 ug |
| T055 | Tissue Transglutaminase Microassay Kit, colorimetric | 1 Kit |
| T056 | Human alpha thrombin, highly active | 200 U |
| T057 | Inhibited human epidermal transglutaminase | 250 ug |
| T061 | Mouse blood coagulation Factor Xlll-A2 | 200 ug |
| T062 | Dog blood coagulation Factor Xlll-A2 | 200 ug |
| T063 | Human blood coagulation Factor Xlll-A2 , Val34Leu-mutant | 200 ug |
| T064 | Inhibited human neuronal transglutaminase | 250 ug |
| T065 | Rat blood coagulation Factor Xlll-A2 | 200 ug |
| T066 | Pig blood coagulation Factor Xlll-A2 | 200 ug |
| T067 | Human tissue transglutaminase (TG2), endotoxin free | 250 ug 1 mg |
| T070 | Human Factor Xllla, Thrombin activated | 200 ug |
| T072 | Dog tissue transglutaminase | 250 ug 1 mg |
| T086 | Human Transglutaminase 5 | 100 ug |
| T087 | Tridegin | 200 ug |
| T092 | Human blood coagulation Factor Xlll-A2 | 100 ug |
| T101 | 1,3,4,5-Tetramethyl-2[(2-oxo-propyl)thio] imidazolium chloride | 10 mg |
| T102 | Mouse Open TG2 | 250 ug 1 mg |
| T106 | Biotinylated human tissue transglutaminase (TG2) | 100 ug 250 ug |
| T108 | Cynomolgus tissue transglutaminase | 250 ug |
| T109 | Cynomolgus open TG2 | 100 ug |
| T1 10 | Recombinant TG2 [E.coli] | 500 ug |
| T1 14 | Blood Coagulation Factor Xlll-Microassay Kit, colorimetric | 1 Kit |
| T117 | Biotinylated inactive hTG2 (Cys277Ser) | 250 ug 1 mg |
| T122 | Recombinant TG2 (insect cells) | 500 ug |
| T123 | Biotinylated human tissue transglutaminase (TG2) | 50 ug |
| T124 | Recombinant TG3 (insect cells) | 400 ug |
| T127 | Biotinylated human blood coagulation Factor XIII | 50 ug |
| T134 | Open tTG™ | 100 ug |
| T139 | Rabbit tissue transglutaminase | 250 ug 1mg |
| T140 | Biotinylated human epidermal transglutaminase | 100 ug |
| T141 | Biotinylated human neuronal transglutaminase | 100 ug |
| T142 | Biotinylated mouse blood coagulation Factor Xlll-A2 | 50 ug |
| T146 | Mouse neuronal transglutaminase | 250 ug |
| T148 | Biotinylated human Open tTG™ | 50 ug 1 mg |
| T149 | Oxidized inactive human tissue transglutaminase | 250 ug 1 mg |
| T150 | Biotinylated mouse open TG2 | 50 ug |
| T151 | Biotinylated oxidized inactive human tissue transglutaminase | 250 ug 1 mg |
| T152 | Rabbit blood coagulation Factor Xlll-A2 | 200 ug |
| T153 | Microbial (bacterial) transglutaminase, edotoxin free | 25 U;10x 25 U;20x 25 U |
| T156 | Biotinylated mouse tissue transglutaminase | 250 ug; 1 mg |
| T159 | Pig tissue transglutaminase | 250 ug; 1 mg |
| T160 | Biotinylated cynomolgus tissue transglutaminase | 50 ug |
| T161 | Cynomolgus blood coagulation Factor Xlll-A2 | 200 ug |
| T167 | Short human tissue transglutaminase, aa 1-475 | 250 ug |
| T168 | Human tissue transglutaminase, C23OA mutant | 250 ug;1 mg |
| T169 | Human tissue transglutaminase, R580A mutant | 250 ug;1 mg |
| T173 | Human tissue transglutaminase, R116C mutant | 1 mg |
| T178 | Microbial transglutaminase with C-terminal His6-tag | 25 U;10 x 25 U;20 x 25 U |
| T184 | Cat tissue transglutaminase | 200 ug |
| T187 | Factor XIII activation peptide, recombinant | 500 ug |
| T197 | Coagulation factor XIII, recombinant human Factor Xlll-A2 | 100E;250E |
| T222 | Human alpha Thrombin, recombinant | 100 NIH Units |
| Z004 | Z-Gln-GIn-Pro-Leu-OH | 25 mg |
| Z006 | Z-DON-Val-Pro-Leu-OMe,"Z-DON" | 10 mg |
| Z009 | ZediXclusive Microbial Transglutaminase Assay Kit | 1 Kit |
| Z010 | ZediXclusive Tissue Transglutaminase Assay Kit | 1 Kit |
| Z011 | Z-(D)-DON-Val-Pro-Leu-OMe | 10 mg |
| Z013 | Z-MA-QPL-OMe | 10 mg |
| Z015 | Keillor inhibitor AA9 | 10 mg |
| Z016 | Keillor inhibitor NC9 | 10 mg |
| Z017 | Keillor inhibitor VA4 | 10 mg |
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771149750
传真:18327026838
邮箱:sales@amyjet.com
0.3721